"Rapid progress in partnering discussions. On 12 February 2025, the Company announced that it was in confidential discussions with a potential partner regarding an in-licensing opportunity and that it expected to submit an initial non-binding indicative offer by the end of February.
On 24 February2025, the Company announced that a non-binding offer had been submitted.
The asset in question is a ‘clinic-ready’ program in a neurological rare disease, currently underdevelopment by a large international pharmaceutical company. Post-period, on 2 April 2025, the Company disclosed that it continued to pursue additional confidential in-licensing discussions with other companies and was considering the submission of further non-binding proposals.
Percheron continues to move forward actively with these negotiations and will endeavour to provide additional clarity to investors as discussions progress, and as circumstances allow."
Meanwhile, the 'ANN - Update on Partnering Progress' on 24 Feb 25 stated: "The proposal remains subject to further negotiation, and to execution of a definitive agreement. The Company estimates at this stage that it would take 8-12weeks to negotiate and sign a definitive agreement."
8 to 12 weeks means anywhere between NOW and 19th May 2025.
PER has been cagey on details (understandably), but lets consolidate any news or suspicions here of what PER will be spending our war chest of $millions on.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)